Researchers report a synthetic molecule can reduce tau and even reverse some neurological damage in mouse models of Alzheimer's disease.
Zolgensma, an FDA approved gene therapy, supplements the production of the SMN protein to improve motor neuron function in children with spinal muscular atrophy after just one dose.
A new study implicates a key cellular mechanism as defective in SMA for the first time, providing a new lead for developing future interventions.
Researchers identify Neurexin2 as a new target for potential treatment of spinal muscular atrophy.
A study suggests that spinal muscular atrophy (SMA), a genetic neuromuscular disease in infants and children, results primarily from motor circuit dysfunction, not motor neuron or muscle cell dysfunction, as is commonly thought. In a second study, the researchers identified the molecular pathway in SMA that leads to problems with motor function.
A new study reveals a link between brain activation, cardiorespiratory fitness and executive function in older adults.
GABA plays a vital role in controlling the involuntary tics associated with Tourette Syndrome.